J. Thipphawong

J. Thipphawong, J. Okikawa, C. M. Bowman, 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.

D. Scheifele, J. Thipphawong, L. Barreto, 1995, Vaccine.

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain

M. Hanna, J. Thipphawong, A. Tuca, 2009, BMC palliative care.

FTS3-01-03 PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLYALZHEIMER’S DISEASE WITH LANABECESTAT FINAL EFFICACY, SAFETYAND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZH

R. Sperling, P. Aisen, M. Donohue, 2019 .

Results of a Double‐blind, Placebo‐controlled, Fixed‐dose Assessment of Once‐daily OROS® Hydromorphone ER in Patients with Moderate to Severe Pain Associated with Chronic Osteoarthritis

R. Rauck, J. Thipphawong, R. Rapoport, 2013, Pain practice : the official journal of World Institute of Pain.

Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.

I. C. Tudor, J. Thipphawong, S. Khanna, 2007, Clinical therapeutics.

Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO‑127)

M. Wallace, R. Skowroński, J. Thipphawong, 2007, Current medical research and opinion.

The pharmacokinetics of a long-acting OROS hydromorphone formulation

J. Turgeon, U. Richarz, J. Thipphawong, 2010, Expert opinion on drug delivery.

A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain

M. Hanna, J. Thipphawong, 2008, BMC palliative care.

A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain

J. Thipphawong, Magdi Hanna, 2008, BMC palliative care.

Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol

J. Thipphawong, K. Sivakumar, G. Sathyan, 2008, Current medical research and opinion.

Analgesic Efficacy of Inhaled Morphine in Patients after Bunionectomy Surgery

J. Thipphawong, N. Babul, B. Otulana, 2003, Anesthesiology.

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.

R. Sperling, P. Aisen, M. Donohue, 2021, JAMA neurology.

Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release Hydromorphone

E. Sellers, I. C. Tudor, M. Shram, 2010, Journal of clinical psychopharmacology.

Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

N. Slatkin, J. Thipphawong, P. Sanga, 2019, The journal of pain : official journal of the American Pain Society.

Long‐Term Safety and Efficacy of Fulranumab in Patients With Moderate‐to‐Severe Osteoarthritis Pain: A Phase II Randomized, Double‐Blind, Placebo‐Controlled Extension Study

Nathaniel Katz, J. Haeussler, J. Thipphawong, 2017, Arthritis & rheumatology.

Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma.

J. Thipphawong, J. Okikawa, B. Otulana, 2004, International journal of clinical pharmacology and therapeutics.

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in treatment of patients with moderate-to-severe osteoarthritis pain

J. Haeussler, J. Thipphawong, N. Katz, 2011 .

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

J. Haeussler, J. Thipphawong, N. Katz, 2013, PAIN®.

Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.

J. Thipphawong, P. Sanga, K. Kelly, 2016, Clinical therapeutics.

Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies

J. Haeussler, J. Thipphawong, P. Sanga, 2019, Current medical research and opinion.

Safety and Efficacy of Fulranumab in Osteoarthritis of the Hip and Knee: Results From Four Randomized, Double-blind, Placebo-controlled Phase III Studies

J. Haeussler, J. Thipphawong, P. Sanga, 2019 .

An Evaluation of the Safety and Immunogenicity of a Five-Component Acellular Pertussis, Diphtheria, and Tetanus Toxoid Vaccine (DTaP) When Combined With a Haemophilus influenzaeType b-Tetanus Toxoid Conjugate Vaccine (PRP-T) in Taiwanese Infants

Chin‐Yun Lee, Li-Min Huang, P. Lee, 1999, Pediatrics.

Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo‐ and active‐controlled trial

J. Thipphawong, A. Mayorga, K. Kelly, 2016, International journal of clinical practice.

Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain.

M. Wallace, J. Thipphawong, 2010, Pain medicine.

Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

I. C. Tudor, M. Wallace, D. Moulin, 2008, The Journal of international medical research.

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study

I. C. Tudor, M. Wallace, D. Moulin, 2007, International journal of clinical practice.

Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food

Suneel K. Gupta, J. Thipphawong, G. Sathyan, 2007, BMC clinical pharmacology.

Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone

Suneel K. Gupta, J. Thipphawong, G. Sathyan, 2007 .

Research article A randomized, double-blind comparison of OROS ® hydromorphone and controlled-release morphine for the control of chronic cancer pain

M. Hanna, J. Thipphawong, 2008 .

Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.

I. C. Tudor, M. Wallace, D. Moulin, 2018, Journal of opioid management.

Efficacy of the Sustained-Release Hydromorphone in Neuropathic Pain Management: Pooled Analysis of Three Open-Label Studies

M. Wallace, D. Moulin, U. Richarz, 2010, Journal of pain & palliative care pharmacotherapy.

Measles vaccination of infants in a well‐vaccinated population

H. Pabst, M. M. Carson, J. Thipphawong, 1995, The Pediatric infectious disease journal.

Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat

G. Novak, Qingqin S. Li, J. Snoeys, 2023, BMC Genomics.

J. Thipphawong, P. Sanga, K. Kelly, 2016, Clinical therapeutics.

(382) Efficacy, safety, and tolerability of Fulranumab as adjunctive therapy for cancer-related pain: a randomized, double-blind, placebo-controlled, multicenter study.

N. Slatkin, J. Thipphawong, P. Sanga, 2016, The journal of pain : official journal of the American Pain Society.

Efficacy of the Sustained-Release Hydromorphone in Neuropathic Pain Management: Pooled Analysis of Three Open-Label Studies

M. Wallace, D. Moulin, U. Richarz, 2010, Journal of pain & palliative care pharmacotherapy.